Chemoinformaics analysis of 4-Bromoadamantan-2-ol
| Molecular Weight | 231.133 | nRot | 0 |
| Heavy Atom Molecular Weight | 216.013 | nRig | 30 |
| Exact Molecular Weight | 230.031 | nRing | 4 |
| Solubility: LogS | -3.582 | nHRing | 0 |
| Solubility: LogP | -0.459 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 4 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 15 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 30.5539 |
| nHD | 1 | BPOL | 16.4281 |
| QED | 0.172 |
| Synth | 4.689 |
| Natural Product Likeliness | 2.111 |
| NR-PPAR-gamma | 0.939 |
| Lipinski | Rejected |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.002 |
| Pgp-sub | 0.96 |
| HIA | 0.982 |
| CACO-2 | -6.32 |
| MDCK | 0.0000382 |
| BBB | 0.168 |
| PPB | 0.831055 |
| VDSS | 0.78 |
| FU | 0.213838 |
| CYP1A2-inh | 0.009 |
| CYP1A2-sub | 0.021 |
| CYP2c19-inh | 0.01 |
| CYP2c19-sub | 0.053 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.295 |
| CYP2d6-inh | 0.002 |
| CYP2d6-sub | 0.149 |
| CYP3a4-inh | 0.014 |
| CYP3a4-sub | 0.007 |
| CL | 1.235 |
| T12 | 0.364 |
| hERG | 0.017 |
| Ames | 0.772 |
| ROA | 0.158 |
| SkinSen | 0.038 |
| Carcinogencity | 0.079 |
| EI | 0.007 |
| Respiratory | 0.02 |
| NR-Aromatase | 0.96 |
| Antiviral | No |
| Prediction | 0.914735 |